KLDO - Kaleido BioSciences, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
8.95
+0.31 (+3.59%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close8.64
Open9.08
Bid0.00 x 900
Ask0.00 x 1000
Day's Range8.90 - 9.79
52 Week Range6.23 - 19.00
Volume252,240
Avg. Volume65,246
Market Cap267.003M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-6.24
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est17.88
Trade prices are not sourced from all markets
  • Microbiome biotechs grapple with how to protect their IP
    American City Business Journals

    Microbiome biotechs grapple with how to protect their IP

    Microbiome companies face an added complication that other drugmakers may not when trying to maintain an exclusive hold on their products: It’s not possible to patent a naturally occurring substance like plants or bacteria.

  • GlobeNewswire

    Kaleido Biosciences Reports Second Quarter 2019 Financial Results and Provides Corporate Update

    LEXINGTON, Mass., Aug. 01, 2019 -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the potential of.

  • GlobeNewswire

    Kaleido Biosciences to Present at the 39th Annual Canaccord Genuity Growth Conference

    Kaleido Biosciences, Inc. (KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the potential of the microbiome organ to treat disease and improve human health, today announced that management will participate in a fireside chat at the 39th Annual Canaccord Genuity Growth Conference in Boston, MA on Thursday, August 8, 2019 at 1:00 p.m. ET. A live audio webcast will be available through the Investors & Media section of Kaleido’s website at https://investors.kaleido.com/events-presentations.  An archived replay will be accessible for 90 days following the event. Kaleido Biosciences is a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the potential of the microbiome organ to treat disease and improve human health.

  • GlobeNewswire

    Kaleido Biosciences Appoints Jerald Korn as General Counsel and Corporate Secretary

    Kaleido Biosciences, Inc. (KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the potential of the microbiome organ to treat disease and improve human health, today announced the appointment of Jerald Korn as General Counsel and Corporate Secretary, reporting to President and Chief Executive Officer, Alison Lawton. “Jerald brings an in-depth understanding of strategy and operations in growth-stage organizations and more than 15 years of experience guiding the executive teams of some of the leading public life science companies,” said Alison Lawton, President and Chief Executive Officer of Kaleido. “As we continue to advance our business, Kaleido will benefit from Jerald’s proven success helping companies navigate expansion, transactions and commercializing products that can improve patients’ lives.

  • How Many Kaleido BioSciences, Inc. (NASDAQ:KLDO) Shares Did Insiders Buy, In The Last Year?
    Simply Wall St.

    How Many Kaleido BioSciences, Inc. (NASDAQ:KLDO) Shares Did Insiders Buy, In The Last Year?

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...

  • GlobeNewswire

    Kaleido Biosciences Announces Appointment of Theo Melas-Kyriazi to its Board of Directors

    Kaleido Biosciences, Inc. (KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the potential of the microbiome organ to treat disease and improve human health, today announced that Theo Melas-Kyriazi, Executive Partner at Flagship Pioneering, has been appointed to its Board of Directors. In addition, the Company announced that Noubar Afeyan, Ph.D., co-founder of Kaleido and CEO of Flagship Pioneering, is stepping down after serving as a Board member since Kaleido’s founding within Flagship Labs in 2015.

  • GlobeNewswire

    Kaleido Biosciences to Highlight Chemistry-Driven Approach at Microbiome Movement – Drug Development Summit

    Kaleido Biosciences, Inc. (KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the potential of the microbiome organ to treat disease and improve human health, today announced that members of the Company’s leadership team will be featured speakers at the 4th Microbiome Movement – Drug Development Summit which is being held today through June 28, 2019 in Boston.

  • GlobeNewswire

    Kaleido Biosciences to Present at the Goldman Sachs 40th Annual Global Healthcare Conference

    LEXINGTON, Mass., June 03, 2019 -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging.

  • In slow year for life science IPOs, this venture firm is making big money
    American City Business Journals

    In slow year for life science IPOs, this venture firm is making big money

    The slowing of Massachusetts biotech and medical device companies’ stock market launches has left most venture creation firms without exit opportunities, except for one.

  • GlobeNewswire

    Kaleido Biosciences Reports First Quarter 2019 Financial Results and Provides Corporate Update

    LEXINGTON, Mass., May 02, 2019 -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging.

  • MoneyShow

    Long-Term "GameChangers" in Biotech

    When I'm hunting for unicorns, I start with biotech. They won't all be winners. But in a well-constructed portfolio, enough of them will hit their commercial targets with sufficient force to make their shareholders very happy, explains Hilary Kramer, editor of GameChangers.

  • GlobeNewswire

    Kaleido Biosciences Announces Presentation of Clinical Study and Ex Vivo Data Supporting the Development of Novel Microbiome Metabolic Therapies for Hyperammonemia at The International Liver Congress™ 2019 (EASL)

    The gut microbiome plays a significant role in the production and consumption of ammonia, which is central to the pathogenesis of several ammonia processing-related diseases. Kaleido is currently advancing novel MMT product candidates, KB195 and KB174, targeted at reducing net ammonia production by modulating the metabolic output and profile of the microbiome. “These data demonstrate the potential of our MMTs to reduce ammonia produced by the gut microbiome and support the development of lead candidates for the treatment of diseases resulting in hyperammonemia,” said Katharine Knobil, M.D., Chief Medical Officer and Head of Research & Development at Kaleido.

  • GlobeNewswire

    Kaleido Biosciences Announces Key Appointments to Leadership Team

    LEXINGTON, Mass., April 08, 2019 -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging.

  • GlobeNewswire

    Kaleido Biosciences Announces Upcoming Presentations at the Society for Inherited Metabolic Disorders Annual Meeting and The International Liver Congress™ (EASL)

    Posters to feature ex vivo and in-human data supporting Kaleido’s Microbiome Metabolic Therapy programs for the treatment of hyperammonemia LEXINGTON, Mass., March 27, 2019 --.

  • GlobeNewswire

    Kaleido Biosciences Announces Initiation of Dosing in Non-IND Clinical Studies in Patients with Urea Cycle Disorders and Cirrhosis

    Kaleido Biosciences, Inc. (KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the potential of the microbiome organ, today announced the initiation of dosing in two non-Investigational New Drug (non-IND) clinical studies evaluating KB195 in patients with urea cycle disorders (UCD) and KB174 in patients with cirrhosis.  A third non-IND clinical study evaluating various doses of KB174 in healthy subjects is also underway. The gut microbiome plays a significant role in the production and consumption of ammonia, which is central to the pathogenesis of several ammonia processing-related diseases. “As we continue to advance the development of our novel MMTs, we are pleased to have initiated dosing in these patient studies and anticipate results during the fourth quarter of 2019,” said Alison Lawton, President and Chief Executive Officer of Kaleido.

  • GlobeNewswire

    Kaleido Biosciences to Highlight its Platform to Identify and Evaluate Microbiome Metabolic Therapies to Reduce Gut Ammonia Production in Presentation at Keystone Symposia on Microbiome

    Kaleido Biosciences, (KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the potential of the microbiome organ to treat disease and improve human health, today announced that a scientific poster and presentation describing its proprietary product platform and the identification of its lead product candidate, KB195, will be featured during the Keystone Symposia meeting, Microbiome: Chemical Mechanisms and Biological Consequences, which will be held from March 10-14, 2019, in Montreal, Québec. The poster entitled, “Developing a Drug Discovery Platform to Target Gut Microbiota-Associated Ammonia Production,” will be displayed during Poster Session 2 from 7:30-10:00 pm ET on Tuesday, March 12, 2019.

  • GlobeNewswire

    Kaleido Biosciences Announces Closing of Initial Public Offering

    Kaleido Biosciences, Inc. (KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the potential of the microbiome organ to treat disease and improve human health, today announced the closing of its initial public offering of 5,000,000 shares of common stock at a public offering price of $15.00 per share. All of the shares in the offering were offered by Kaleido. Goldman Sachs, J.P. Morgan and Morgan Stanley acted as joint book-running managers for the offering. Canaccord Genuity acted as lead manager for the offering.

  • GlobeNewswire

    Nasdaq Welcomes Kaleido Biosciences, Inc. (Nasdaq: KLDO) to the Nasdaq Stock Market

    Kaleido Biosciences, Inc. (KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach focused on leveraging the potential of the microbiome organ to treat disease and improve human health, rang the Nasdaq MarketSite bell in Times Square today in celebration of its initial public offering (IPO) on The Nasdaq Stock Market. Kaleido has built a human-centric proprietary product platform to enable the rapid and cost-efficient discovery and development of novel Microbiome Metabolic Therapies (MMT™).  The Company is advancing a broad pipeline of MMT candidates with the potential to address a variety of diseases and conditions with significant unmet patient needs. “We are excited to join Nasdaq as we continue to work to translate the promise of the microbiome into solutions for patients,” said Alison Lawton, President and Chief Executive Officer, Kaleido.

  • GlobeNewswire

    Kaleido Biosciences Announces Pricing of Initial Public Offering

    Kaleido Biosciences, Inc. (KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the potential of the microbiome organ to treat disease and improve human health, today announced the pricing of its initial public offering of 5,000,000 shares of common stock at a public offering price of $15.00 per share, before underwriting discounts and commissions. In addition, Kaleido has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of common stock at the initial public offering price, less the underwriting discounts and commissions. Kaleido’s common stock is expected to begin trading on The Nasdaq Global Select Market on February 28, 2019, under the ticker symbol “KLDO.” All of the common stock in the offering is being offered by Kaleido.

  • Benzinga

    IPO Outlook For The Week: Gaming And Biotech

    For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . IPO dates below are expected but not confirmed. Super League Gaming, Inc. (SLGG) will issue nearly 2.3 million shares between ...